ATLANTA--(BUSINESS WIRE)--Sept. 19, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for...
#72: MIVT News MIV Therapeutics Appoints Mid-America Heart Institute Director Dr. David Cohen to Scientific Advisory Board; Respected Interventional Cardiologist to Assist Commercialization of MIVT Technologies for Safer Cardiovascular Stents
ATLANTA--(BUSINESS WIRE)--Sept. 15, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for...
#71: MIVT News MIV Therapeutics Names Harvard Interventional Cardiologist Dr. Joseph Carrozza to Scientific Advisory Board; Industry Authority to Help Guide Development of MIVT's Unique Coatings for Highly Biocompatible Cardiovascular Stents
ATLANTA--(BUSINESS WIRE)--Sept. 14, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for...
#70: MIVT News MIV Therapeutics Enters into Agreement to Acquire Vascore Medical Co. Ltd., Leading Chinese Manufacturer of Advanced Cardiovascular Stents; Agreement Brings MIVT Manufacturing Operation and Distribution in Growing Asian Market
VANCOUVER, B.C.--(BUSINESS WIRE)--Sept. 13, 2006--MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for...
#69: MIVT News MIV Therapeutics Subsidiary Invited to Present Groundbreaking Stroke-Prevention Device at Top International Symposium; SagaX to Spotlight Latest Developments to Commercialize Unique Implantable Embolic Filter at TCT2006 Conference
ATLANTA--(BUSINESS WIRE)--Aug. 25, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
#68: MIVT News MIV Therapeutics to Hold Annual Shareholder Meeting on Thursday, August 24; Company Officers to Review Past Milestone Achievements and Business Initiatives for Coming Year
ATLANTA--(BUSINESS WIRE)--Aug. 23, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
#67: MIVT News MIV Therapeutics Files Three New US Patents for Breakthrough Stroke-Preventing Technology from SagaX Subsidiary; Company Expands Intellectual Property Leadership in $1.8 Billion Market for Revolutionary Implantable Devices
ATLANTA--(BUSINESS WIRE)--Aug. 18, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
#66: MIVT News MIV Therapeutics to Present Advanced Biocompatible Stent-Coating Technology at International Biomaterials Conference; Senior Scientist Invited to Review Data at 19th International Symposium on Ceramics in Medicine in China
ATLANTA--(BUSINESS WIRE)--Aug. 15, 2006--MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
ATLANTA--(BUSINESS WIRE)--Aug. 10, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
ATLANTA--(BUSINESS WIRE)--July 17, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular...
#63: MIVT News Web Alert: MIVT to Hold Investor Conference Call at 12:00 p.m. Eastern Today; President Dr. Mark Landy to Discuss Scientific Evidence Validating Company's Innovative Program to Create Safer, Better Stents
VANCOUVER, British Columbia--(BUSINESS WIRE)--July 11, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery...
#62: MIVT News MIV Therapeutics to Hold Investor Conference Call at 12:00 PM Eastern Tuesday, July 11; Company President Mark Landy to Update Investors on Key Data Validating MIVT's Program to Create Safer, Better Coronary Stents
VANCOUVER, British Columbia--(BUSINESS WIRE)--July 10, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery...
#61: MIVT News MIV Therapeutics informiert Anleger über wichtige wissenschaftliche Daten zur Bestätigung des Nutzens der biokompatiblen Stent-Technologie der Gesellschaft
VANCOUVER, British Columbia--(BUSINESS WIRE)--7. Juli 2006-- President Mark Landy wird am 11. Juli Konferenzschaltung zur Diskussion bahnbrechender Daten zur Hydroxyapatit-Verträglichkeit...
#60: MIVT News MIV Therapeutics Updates Investors on Key Scientific Data Supporting Advantages of Company's Biocompatible Stent Technology; Company President Mark Landy to Host July 11 Conference Call to Discuss Breakthrough Data on Hydroxyapatite Safety
VANCOUVER, British Columbia--(BUSINESS WIRE)--July 7, 2006--MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems...
#59: MIVT News MIVT beruft sich auf eine steigende Anzahl von Nachweisen, die die Unternehmensstrategie für die Entwicklung sicherer und besserer kardiovaskulärer Stents bestätigen
VANCOUVER, British Columbia--(BUSINESS WIRE)--6. Juli 2006-- die eigenen Lösungen des Unternehmens, die weitreichenden medizinischen Bedenken Rechnung tragen, werden im Wall Street Journal...
